Letters

LETTERS TO THE EDITOR
Anomalous short plasma elimination half life in a patient intoxicated with bismuth subcitrate SIR,-The report by Playford et al ' provides important information. There is only one other report of bismuth intoxication with the use of the subcitrate formulation in humans.2 This report was marred by the absence of assay data.
The levels reported by Playford et al are well outside the values reported from other studies involving bismuth subcitrate (Table) .8 These increased levels are consistent with a doubling of dose and renal impairment, if it is assumed that bismuth clearance reduces proportionally to creatinine clearance. Specifically, if upper steady-state limits of 58 tg/l are assumed in patients with normal renal clearance (-120 ml/ min) (see Table) ,6 and a creatinine clearance of 15 ml/min in the patient is assumed (case report value), then upper limits of 480 tig/l could be predicted. If daily doses were doubled, then values of 960 tgl would be predicted, in close accord with the case report values of 880 tg/l. ' There is, however, an anomaly related to estimated half life of elimination in plasma in this patient. We derive a value of 13-15 days from the published figure using terminal phase data. Previous reports of elimination half life values in both urine and plasma in the normal range of plasma bismuth concentrations6 and in intoxicated patientse give values of 18-20 days. If renal elimination alone determines elimination half life, then a longer half life should have resulted with prolongation proportional to renal clearance change.
There is evidence in both animals and humans for excretion of bismuth into gut via bile on acute dosing." 2 Such a mechanism of parallel, extrarenal elimination would need to be invoked to allow preservation of a short half life as reported. The apparent anomaly of a high level and a short half life can be resolved if altered absorption is proposed together with parallel hepatic and renal clearance. The altered absorption in this patient reported by Playford and coworkers' may be explained by upper gastrointestinal surgery with rapid gastric emptying.
Because of direct relevance to this discussion we present preliminary data from three Biliary (B) and urinary (U) clearances (mllmin) of bismuth in each ofthree patients (1, 2, and 3). These patients had a biliary T-tube in the common bile duct after cholecystectomy and were given 107 7 mg bismuth in theform ofchew colloidal bismuth subcitrate tablets (Denol)four times a dayforfour days.
Until another class of agents is discovered with equal efficacy'4-'7 there will be a need to continue the use of bismuth in type B gastritis and ulcer disease.'8 There is a need to understand the processes of bismuth handling before restriction policies can be made. Caution must be exercised in patients with renal impairment and possibly hepatic impairment. The ready availability of simple assays'3 allows plasma monitoring to be used to optimise safe usage, according to accepted plasma level guidelines. 9 
